Date	e:2023/03	/12	
You	r Name: Peigu	ıan Zhu	
Mar	nuscript Title: Constru	uction of a prognostic m	nodel for lung adenocarcinoma based on membrane-
tens	sion-related genes		
Mar	nuscript number (if known)	•	
related to the man to the med	ted to the content of your ries whose interests may be ransparency and does not ries tionship/activity/interest, if following questions apply fuscript only.  author's relationships/active epidemiology of hypertelication, even if that medicatem #1 below, report all supplies whose interesting the supplies and the supplies that medicatem #1 below, report all supplies whose interesting the supplies are the supplies that medicatem #1 below, report all supplies the supplies that medicatem #1 below, report all supplies the supplies that medicatem #1 below, report all supplies the supplies that medicatem #1 below, report all supplies the supplies that medicatem #1 below, report all supplies the supplies that medicatem #1 below, report all supplies the supplies that medicatem #1 below, report all supplies the supplies that medicatem #1 below, report all supplies the supplies that medicatem #1 below, report all supplies the supplies that medicatem #1 below is the supplies that medicatem #1 below, report all supplies the supplies that medicatem #1 below is the supplies that medica	manuscript. "Related" mean affected by the content of the author's relationship to the content of th	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
the	time frame for disclosure is	the past 36 months.	
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	X None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4

Consulting fees

X\_\_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		
		ı	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/03/	12	
Your Name:	Zhang	yu Teng	
<b>Manuscript Title</b>	e: Constru	ction of a prognostic m	odel for lung adenocarcinoma based on membrane-
tension-relate	d genes		
Manuscript nun	nber (if known):		
related to the coparties whose into transparency relationship/act The following quanuscript only The author's relation the epidemic	ontent of your n nterests may be and does not no tivity/interest, it uestions apply to Lationships/activology of hyperte	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias. is preferable that you do o the author's relationship vities/interests should be	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		the past 36 months.	d in this manuscript without time limit. For all other items
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed)	
		Time frame: Since the initia	al planning of the work
1 All support	for the present	X None	
	(e.g., funding,		
	study materials,		
medical wri			
	charges, etc.)		
	it for this item.		
		Time frame: pas	t 36 months
2 Grants or co	ontracts from	X None	
	if not indicated		
in item #1 a			
3 Royalties or		X None	
7			
4 Consulting f	fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		
		ı	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2023/03/	12	
You	r Name: Wenx	ing Yang	
Mar	nuscript Title: Constru	ction of a prognostic mo	odel for lung adenocarcinoma based on membrane-
tens	sion-related genes		
Mar	nuscript number (if known):		
related to the relate	ted to the content of your name ites whose interests may be ransparency and does not not itenship/activity/interest, it following questions apply to itenships only.  author's relationships/activity of hyperterestication, even if that medical	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship wities/interests should be dension, you should declare a tion is not mentioned in the port for the work reported	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		
		ı	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date:	2023/03/	12	
<b>Your Name</b>	: Dengg	guo Zhang	
Manuscript	: Title: Constru	ction of a prognostic m	odel for lung adenocarcinoma based on membrane-
tension-re	lated genes		
Manuscript	number (if known):		
related to t parties who to transpar relationship The followi manuscript The author to the epide medication In item #1 k	the content of your mose interests may be ency and does not not activity/interest, it only.  It is relationships/active emiology of hyperter, even if that medical pelow, report all suppelors.	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do to the author's relationship wities/interests should be insion, you should declare tion is not mentioned in t	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initia	al planning of the work
manus provisi medica proces	port for the present cript (e.g., funding, on of study materials, all writing, article sing charges, etc.) e limit for this item.	XNone	
		Time frame: pas	et 36 months
any en	or contracts from tity (if not indicated #1 above).	XNone	
3 Royalti	es or licenses	XNone	
4 Consul	ting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		
		ı	

None			

Please place an "X" next to the following statement to indicate your agreement:

<b>Date</b>	:2023/03	3/12	
Your	Name: Biao	Wang	
Man	uscript Title: Constr	ruction of a prognostic m	odel for lung adenocarcinoma based on membrane-
tens	ion-related genes	_	
Man	uscript number (if known	):	
relat parti to tra relat The f man The a to th medi	ed to the content of your es whose interests may be an sparency and does not ionship/activity/interest, following questions apply uscript only.  Buthor's relationships/activity of hypertication, even if that medical	manuscript. "Related" mea e affected by the content of necessarily indicate a bias. it is preferable that you do to the author's relationshit civities/interests should be ension, you should declare cation is not mentioned in t	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
	ime frame for disclosure		Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
	All Colons	Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials		
	medical writing, article	,	
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in item #1 above).		
3	Royalties or licenses	X None	
J	no parties of necrises		

\_None

Χ\_

Consulting fees

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		
		ı	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2023/03/	′12	
	r Name: Ze Yaı		
Vlar	nuscript Title: Constru	ection of a prognostic m	odel for lung adenocarcinoma based on membran
ens	sion-related genes		
Vlar	nuscript number (if known):		
rela part to tr rela The	ted to the content of your n ies whose interests may be ansparency and does not no tionship/activity/interest, it	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. t is preferable that you do	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.  ps/activities/interests as they relate to the current
o th nec n it	ne epidemiology of hyperte lication, even if that medica	nsion, you should declare a ation is not mentioned in the port for the work reported	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive he manuscript.  d in this manuscript without time limit. For all other item
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		
		ı	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2023/03	/12	
You	r Name: Kaiq	ang Wang	
Maı	nuscript Title: Constr	uction of a prognostic model	for lung adenocarcinoma based on membrane-
ten	sion-related genes		
Maı	nuscript number (if known		
rela part to to trela The mar	ted to the content of your cies whose interests may be ransparency and does not tionship/activity/interest, following questions apply nuscript only. author's relationships/act the epidemiology of hypert	manuscript. "Related" means and affected by the content of the relacessarily indicate a bias. If you it is preferable that you do so. to the author's relationships/act wities/interests should be define	onships/activities/interests listed below that are y relation with for-profit or not-for-profit third nanuscript. Disclosure represents a commitment are in doubt about whether to list a ivities/interests as they relate to the current d broadly. For example, if your manuscript pertains ationships with manufacturers of antihypertensive muscript.
	em #1 below, report all su time frame for disclosure i	-	is manuscript without time limit. For all other items
		Name all entities with whom you have this relationship or indicate none (add rows as	cifications/Comments ., if payments were made to you or to your itution)
		Name all entities with whom you have this relationship or indicate	cifications/Comments ., if payments were made to you or to your itution)
		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial plant  _XNone	cifications/Comments ., if payments were made to you or to your itution)
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial plant XNone	cifications/Comments ., if payments were made to you or to your itution) ning of the work
the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial plant  _XNone	cifications/Comments ., if payments were made to you or to your itution) ning of the work
the 1	All support for the present manuscript (e.g., funding, provision of study materials medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial plant  _XNone  Time frame: past 36 me	cifications/Comments ., if payments were made to you or to your itution) ning of the work
1 2	All support for the present manuscript (e.g., funding, provision of study materials medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial plant XNone XNone  Time frame: past 36 mXNone	cifications/Comments ., if payments were made to you or to your itution) ning of the work
the 1	All support for the present manuscript (e.g., funding, provision of study materials medical writing, article processing charges, etc.)  No time limit for this item.  Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial plant  _XNone  Time frame: past 36 me	cifications/Comments ., if payments were made to you or to your itution) ning of the work

4

Consulting fees

X\_\_None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		
		ı	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2023/03/	12	
You	r Name: Jiangt	ao Pu	
Mar	nuscript Title: Constru	ction of a prognostic mo	odel for lung adenocarcinoma based on membrane-
tens	sion-related genes		
Mar	nuscript number (if known):		
relar part to to to relar The mar to	ted to the content of your name ites whose interests may be ransparency and does not not itenship/activity/interest, it following questions apply to itenships only.  author's relationships/activity of hyperterestication, even if that medical	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do so the author's relationship rities/interests should be dension, you should declare a tion is not mentioned in the port for the work reported	s/activities/interests as they relate to the <u>current</u> <u>efined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your institution)
		none (add rows as	·
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
_			
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	X None	
	financial interests		
		ı	

None			

Please place an "X" next to the following statement to indicate your agreement: